↓ Skip to main content

Biochemical and radiologic improvement in Paget's disease of bone treated with alendronate: A randomized, placebo-controlled trial

Overview of attention for article published in American Journal of Medicine, October 1996
Altmetric Badge

Mentioned by

patent
1 patent

Citations

dimensions_citation
164 Dimensions

Readers on

mendeley
30 Mendeley
You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output. Click here to find out more.
Title
Biochemical and radiologic improvement in Paget's disease of bone treated with alendronate: A randomized, placebo-controlled trial
Published in
American Journal of Medicine, October 1996
DOI 10.1016/s0002-9343(96)00227-6
Pubmed ID
Authors

Ian R. Reid, Geoffrey C. Nicholson, Robert S. Weinstein, David J. Hosking, Tim Cundy, Mark A. Kotowicz, William A. Murphy, Swan Yeap, Suzanne Dufresne, Antonio Lombardi, Thomas A. Musliner, Desmond E. Thompson, A. John Yates

Abstract

The potent bisphosphonates offer great promise in the management of Paget's disease of bone, but are currently available only as parenteral preparations in most countries. There is a need for a well-tolerated, oral therapy. Furthermore, none of the currently available therapies have been rigorously demonstrated to heal the lytic bone lesions characteristic of this condition. Alendronate is a potent new oral aminobisphosphonate that has shown promising effects on Paget's disease in preliminary studies. We report a double-blind, randomized comparison of oral alendronate 40 mg/day and placebo over 6 months in 55 patients with Paget's disease. Efficacy was determined from measurements of biochemical indices of bone turnover (serum alkaline phosphatase and urine N-telopeptide) and blinded radiologic assessment of lytic bone lesions. N-telopeptide excretion declined by 86% and serum alkaline phosphatase by 73% in patients receiving alendronate, but remained stable in patients receiving placebo (P < 0.001 between groups for both indices). Responses were similar whether or not patients had previously received bisphosphonate treatment. Alendronate treatment normalized alkaline phosphatase in 48% of patients. Forty-eight percent of alendronate-treated patients showed radiologic improvement in osteolysis whereas in the placebo group only 4% improved (P = 0.02 for between-groups comparison). No patient in either group showed worsening of osteolysis. Bone histomorphometry indicated that alendronate tended to normalize turnover indices. There was no evidence of abnormal mineralization in bone biopsies taken from 12 alendronate-treated subjects. The treatment was well tolerated. Oral alendronate appears to be a safe and effective therapy for Paget's disease and results in healing of lytic bone lesions.

Mendeley readers

Mendeley readers

The data shown below were compiled from readership statistics for 30 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country Count As %
France 1 3%
Unknown 29 97%

Demographic breakdown

Readers by professional status Count As %
Researcher 5 17%
Student > Ph. D. Student 4 13%
Student > Doctoral Student 4 13%
Student > Bachelor 4 13%
Other 2 7%
Other 6 20%
Unknown 5 17%
Readers by discipline Count As %
Medicine and Dentistry 16 53%
Biochemistry, Genetics and Molecular Biology 2 7%
Pharmacology, Toxicology and Pharmaceutical Science 1 3%
Immunology and Microbiology 1 3%
Environmental Science 1 3%
Other 0 0%
Unknown 9 30%
Attention Score in Context

Attention Score in Context

This research output has an Altmetric Attention Score of 3. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 13 October 2009.
All research outputs
#8,534,528
of 25,373,627 outputs
Outputs from American Journal of Medicine
#3,454
of 7,887 outputs
Outputs of similar age
#8,602
of 27,209 outputs
Outputs of similar age from American Journal of Medicine
#12
of 22 outputs
Altmetric has tracked 25,373,627 research outputs across all sources so far. This one is in the 43rd percentile – i.e., 43% of other outputs scored the same or lower than it.
So far Altmetric has tracked 7,887 research outputs from this source. They typically receive a lot more attention than average, with a mean Attention Score of 17.2. This one is in the 33rd percentile – i.e., 33% of its peers scored the same or lower than it.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 27,209 tracked outputs that were published within six weeks on either side of this one in any source. This one is in the 9th percentile – i.e., 9% of its contemporaries scored the same or lower than it.
We're also able to compare this research output to 22 others from the same source and published within six weeks on either side of this one. This one is in the 4th percentile – i.e., 4% of its contemporaries scored the same or lower than it.